My ePortfolio Register   

Abstract | Full HTML Article | PDF | Portuguese ecancer 9 593 /


Infracentimetric HER-2 positive breast tumours—review of the literature

Breast cancer is the most common malignant neoplasm in the world among women. As a result of the dissemination of population screening programmes, about half of non-metastatic breast cancers are now diagnosed at stage I. 10–15% of T1abN0 tumours over-express human epidermal growth factor (HER-2). These tumours have a globally excellent prognosis, however, treatment with chemotherapy and/or targeted therapy may further improve outcomes in selected cases. In this article, we will review studies with information on prognosis and benefit of adjuvant therapy for T1abN0 HER-2 breast cancer.

Keywords: Breast cancer, infracentimetric, HER-2 positive breast cancer

Loading Article Metrics ... Please wait

Related articles

Research: Nursing intervention in women who developed lymphedema after undergoing a modified radical mastectomy: a pre-experimental study

Abstract | Full Article | PDF | Spanish Published: 19 Apr 2018 /

Research: Evidence on the cost of breast cancer drugs is required for rational decision making

Abstract | Full Article | PDF Published: 16 Apr 2018 /

Review: Adipose tissue stem cells in regenerative medicine

Abstract | Full Article | PDF | Spanish Published: 28 Mar 2018 /

Research: Obesity and outcome of post-menopausal women receiving adjuvant letrozole for breast cancer

Abstract | Full Article | PDF Published: 26 Mar 2018 /

Conference Report: Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18–19 January 2018, Cairo, Egypt

Abstract | Full Article | PDF Published: 22 Mar 2018 /

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence